Respiratorius AB Logo

Respiratorius AB

RESP | SPGR

Overview

Corporate Details

ISIN(s):
SE0004550192 (+2 more)
LEI:
5493001YRVZ5XYFEE615
Country:
Sweden
Address:
Scheeletorget 1, 223 81 Lund
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Respiratorius AB is a research-based pharmaceutical company focused on the development of innovative drug candidates. The company's primary focus is on oncology, specifically creating new treatments for aggressive forms of cancer such as diffuse large B-cell lymphoma (DLBCL). Its lead strategy involves developing a drug candidate intended as a pretreatment to enhance the efficacy of current standard therapies. Founded in 1999 as a spin-off from Lund University, Respiratorius leverages a team with extensive experience in clinical development, commercialization of research, and pharmaceutical business development. While historically involved in developing drugs for COPD and asthma, its current pipeline is centered on cancer.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Respiratorius AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Respiratorius AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Respiratorius AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-12-06 Johan Drott Other Buy 1,120 N/A

Peer Companies

Company Country Ticker View
Kancera Logo
Develops drugs targeting the fractalkine axis for severe inflammation and resistant cancers.
Sweden KAN
Lidds AB Logo
Develops a drug delivery platform for local, sustained-release oncology treatments.
Sweden LIDDS
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies to restore function in neurological & retinal diseases.
Israel LCTX
Lipidor AB Logo
Develops topical skin disease drugs using a lipid-based drug delivery platform.
Sweden LIPI
Lipigon Pharmaceuticals AB Logo
Develops RNA and small-molecule drugs for rare, lipid-related disorders.
Sweden LPGO
Lipum AB Logo
Develops novel antibody therapies for chronic inflammatory diseases like rheumatoid arthritis.
Sweden LIPUM
LYSOGENE Logo France LYS
Lytix Biopharma AS Logo
Develops oncolytic peptides that kill cancer cells and stimulate an anti-tumor immune response.
Norway LYTIX
Matricelf Ltd. Logo
Engineering autologous 3D tissue implants from patient cells to treat spinal cord injuries.
Israel MTLF
Mazaro N.V. Logo
Engineering patented, high-efficiency transmissions for vehicles and industrial drivelines.
Belgium MLMAZ